Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02446743




Registration number
NCT02446743
Ethics application status
Date submitted
6/05/2015
Date registered
18/05/2015
Date last updated
8/11/2018

Titles & IDs
Public title
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents
Scientific title
A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects Who Previously Participated in Parent Studies V72_41 (NCT01423084) and V72P10 (NCT00661713), Compared to Naïve Healthy Controls
Secondary ID [1] 0 0
V72_75
Secondary ID [2] 0 0
205218
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Infections, Meningococcal 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)

Experimental: Group 3B - Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.

Active comparator: Group B_0_1 - Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.


Treatment: Other: rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Subjects With Human Serum Bactericidal Activity (hSBA)=1:4
Timepoint [1] 0 0
Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).
Primary outcome [2] 0 0
Percentage of Subjects With hSBA=1:5
Timepoint [2] 0 0
Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).
Primary outcome [3] 0 0
Percentage of Subjects With hSBA Titers=1:5 in Parent Studies-V72P10 and V72_41
Timepoint [3] 0 0
At one month after last vaccination in parent studies- V72P10 (Month 7) and V72_41 (Month 2)
Primary outcome [4] 0 0
Percentage of Subjects With hSBA=1:8
Timepoint [4] 0 0
Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).
Primary outcome [5] 0 0
Percentage of Subjects With hSBA=1:16
Timepoint [5] 0 0
Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).
Primary outcome [6] 0 0
hSBA Geometric Mean Titers (GMTs) After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study.
Timepoint [6] 0 0
Group 3B: 1 month after the last rMenB+OMV NZ vaccination in parent study and Day 1(prior to booster dose); Group B_0_1: Day 1(prior to first dose)
Primary outcome [7] 0 0
Geometric Mean Ratios (GMRs) of GMTs After the Last Dose of rMenB+OMV NZ Vaccination in the Parent Study Versus Day 1.
Timepoint [7] 0 0
Group 3B: 1 month after the last vaccination in parent study and Day 1 (prior to booster dose)
Primary outcome [8] 0 0
Number of Subjects With Solicited Local and Systemic AEs.
Timepoint [8] 0 0
7 days (including the day of vaccination) after each vaccination
Primary outcome [9] 0 0
Number of Subjects With Any Unsolicited Adverse Events (AEs).
Timepoint [9] 0 0
30 days (including the day of vaccination) after each vaccination.
Primary outcome [10] 0 0
Number of Subjects With Any SAEs, AEs Leading to Withdrawal and Medically Attended AEs.
Timepoint [10] 0 0
Group 3B: from Day 1 to Day 31 (study termination visit) and Group B_0_1: from Day 1 to Day 61 (study termination visit)
Secondary outcome [1] 0 0
Percentage of Subjects With hSBA =1:4 After Booster Dose/First Vaccination of rMenB+OMV NZ.
Timepoint [1] 0 0
Group 3B: 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.
Secondary outcome [2] 0 0
Percentage of Subjects With hSBA =1:5 After Booster Dose/First Vaccination of rMenB+OMV NZ.
Timepoint [2] 0 0
Group 3B: 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.
Secondary outcome [3] 0 0
Percentage of Subjects With hSBA =1:8 After Booster Dose/First Vaccination of rMenB+OMV NZ
Timepoint [3] 0 0
Group 3B : 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.
Secondary outcome [4] 0 0
Percentage of Subjects With hSBA =1:16 After Booster Dose/First Vaccination of rMenB+OMV NZ
Timepoint [4] 0 0
Group 3B: 30 days after booster dose, Group B_0_1 : 30 days after first vaccination.
Secondary outcome [5] 0 0
hSBA Geometric Mean Titers Prior to Booster/First Dose of Vaccination & Post Booster/First Dose of Vaccination.
Timepoint [5] 0 0
Group 3B subjects: Day 1(pre-booster dose) and 30 days post-booster dose. Group B_0_1: Day 1 (pre-first dose) and 30 days post-first dose.
Secondary outcome [6] 0 0
Geometric Mean Ratio (GMRs) of GMTs After Booster Dose/First rMenB+OMV NZ Vaccination Versus Day 1.
Timepoint [6] 0 0
At Day 31 (30 days post booster dose/first dose of vaccination) versus Day 1 (prior to booster dose/first dose of vaccination).
Secondary outcome [7] 0 0
Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Pre Vaccination Compared to One Month Post-booster/First rMenB+OMV NZ Vaccination
Timepoint [7] 0 0
Group 3B: 1 month after booster dose; Group B_0_1: 1 month after first vaccination
Secondary outcome [8] 0 0
Percentage of Subjects With hSBA =1:4 After Booster Dose/Second Vaccination of rMenB+OMV NZ
Timepoint [8] 0 0
Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose.
Secondary outcome [9] 0 0
Percentage of Subjects With hSBA =1:5 After Booster Dose/Second Vaccination of rMenB+OMV NZ
Timepoint [9] 0 0
Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose."
Secondary outcome [10] 0 0
Percentage of Subjects With hSBA =1:8 After Booster Dose/Second Vaccination of rMenB+OMV NZ
Timepoint [10] 0 0
Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose.
Secondary outcome [11] 0 0
Percentage of Subjects With hSBA =1:16 After Booster Dose/Second Vaccination of rMenB+OMV NZ
Timepoint [11] 0 0
Group 3B: 3, 7 and 30 days after third dose booster; Group B_0_1: At 3 (group B_0_1_1 only), 7 (sub-group B_0_1_2 only) and 30 days post-second dose
Secondary outcome [12] 0 0
hSBA Geometric Mean Titers Prior to Booster/Second Dose of Vaccination & Post Booster/Second Dose of Vaccination.
Timepoint [12] 0 0
Group 3B: Day 1 (pre-booster dose) and 3, 7 and 30 days after third dose booster; Group B_0_1: Pre 2nd dose and at 3 (group B_0_1_1 only), 7 (group B_0_1_2 only) and 30 days post second dose.
Secondary outcome [13] 0 0
Geometric Mean Ratios (GMRs) of GMTs After Booster/Second Vaccination Versus Before Booster/Second Vaccination.
Timepoint [13] 0 0
Group 3B: Day 1 and 30 days after third dose booster; Group B_0_1: 30 days post-first dose and at 30 days post-second dose
Secondary outcome [14] 0 0
Percentages of Subjects With at Least Four-fold Increase in hSBA Titers Pre-booster/Second Dose Vaccination- Compared to 3, 7 and 30 Days Post- Booster/Second Vaccination
Timepoint [14] 0 0
Group 3B: at 3, 7 and 30 days after third dose booster; Group B_0_1: at 3 (group B_0_1_1 only), 7 (group B_0_1_2 only) and 30 days post second dose
Secondary outcome [15] 0 0
Percentage of Subjects With hSBA =1:4 After Second Vaccination of rMenB+OMV NZ
Timepoint [15] 0 0
At Day 61 (30 days post second dose of vaccination.)
Secondary outcome [16] 0 0
Percentage of Subjects With hSBA =1:5 After Second Vaccination of rMenB+OMV NZ
Timepoint [16] 0 0
At Day 61 (30 days post second dose of vaccination.)
Secondary outcome [17] 0 0
Percentage of Subjects With hSBA =1:8 After Second Vaccination of rMenB+OMV NZ.
Timepoint [17] 0 0
At Day 61 (30 days post second vaccination)
Secondary outcome [18] 0 0
Percentage of Subjects With hSBA =1:16 After Second Vaccination of rMenB+OMV NZ.
Timepoint [18] 0 0
At Day 61 (30 days post second vaccination)
Secondary outcome [19] 0 0
hSBA Geometric Mean Titers (GMTs) After Second Vaccination of rMenB+OMV NZ.
Timepoint [19] 0 0
At Day 1 & Day 61 (30 days post second dose of vaccination)
Secondary outcome [20] 0 0
Geometric Mean Ratio (GMRs) of GMTs One Month Post Second Vaccination Versus Pre Vaccination at Day 1
Timepoint [20] 0 0
At Day 1 & Day 61 (30 days post 2nd vaccination)
Secondary outcome [21] 0 0
Percentages of Subjects With at Least Four-fold Increase in hSBA Titers at Pre-First Vaccination Compared to One Month Post-Second Vaccination
Timepoint [21] 0 0
At Day 61 (30 days post second dose of vaccination)

Eligibility
Key inclusion criteria
* Inclusion Criterion for follow-on subjects:
* Individuals who participated to Study V72_41 or V72P10 and have completed vaccination with rMenB+OMV NZ according to a 2-dose schedule

Inclusion Criterion for naïve subjects:

* Individuals of 15 through 21 years of age on the day of informed consent and assent as applicable (according to the subject's age) for subjects enrolled at sites that participated to Study V72_41.
* 17 through 24 years of age on the day of informed consent and assent as applicable (according to the subject's age) for subjects enrolled at sites that participated to Study V72P10.

Inclusion Criteria for all subjects:

* Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
* Individuals who can comply with study procedures including follow-up.
* Males Or Females of non-childbearing potential Or Females of childbearing potential who are using an effective birth control method .
Minimum age
15 Years
Maximum age
24 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion Criteria for all subjects

Exclusion Criterion for follow-on subjects:

• Received a third dose of a Meningococcal group B vaccine prior to enrolment in this study.

Exclusion Criterion for naïve subjects:

• Received any other Meningococcal group B vaccines prior to enrolment in this study.

Exclusion Criteria for all subjects:

* Progressive, unstable or uncontrolled clinical conditions.
* Hypersensitivity, including allergy, to any component of vaccines or medical equipment whose use is foreseen in this study.
* Abnormal function of the immune system.
* Received immunoglobulins or any blood products within 180 days prior to informed consent and assent as applicable (according to the subject's age).
* Received an investigational or non-registered medicinal product within 30 days prior to informed consent and assent as applicable (according to the subject's age).
* Study personnel as an immediate family or household member.
* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.
* Positive results at the urine pregnancy test performed before study vaccination.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/11/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/09/2016
Sample size
Target
Accrual to date
Final
531
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Sherwood
Recruitment hospital [2] 0 0
GSK Investigational Site - North Adelaide
Recruitment hospital [3] 0 0
GSK Investigational Site - Carlton
Recruitment hospital [4] 0 0
GSK Investigational Site - Subiaco
Recruitment postcode(s) [1] 0 0
4075 - Sherwood
Recruitment postcode(s) [2] 0 0
5006 - North Adelaide
Recruitment postcode(s) [3] 0 0
3010 - Carlton
Recruitment postcode(s) [4] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Nova Scotia
Country [2] 0 0
Canada
State/province [2] 0 0
Ontario
Country [3] 0 0
Chile
State/province [3] 0 0
Santiago

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose/aim of this study is to assess 1) the long-term persistence (4 to 7.5 years after the last dose) of bactericidal activity following primary vaccination with rMenB+OMV NZ in adolescents \[who previously participated in parent studies V72_41 (NCT0142384) and V72P10 (NCT00661713)\] and 2) the kinetics of immune response following booster vaccination with rMenB+OMV NZ
Trial website
https://clinicaltrials.gov/study/NCT02446743
Trial related presentations / publications
Nolan T, Santolaya ME, de Looze F, Marshall H, Richmond P, Henein S, Rheault P, Heaton K, Perrett KP, Garfield H, Gupta A, Ferguson M, D'Agostino D, Toneatto D, O'Ryan M. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019 Feb 21;37(9):1209-1218. doi: 10.1016/j.vaccine.2018.12.059. Epub 2019 Jan 26.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02446743